Patents by Inventor Pedro Berraondo Lopez
Pedro Berraondo Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
Publication number: 20230112986Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).Type: ApplicationFiled: July 21, 2022Publication date: April 13, 2023Applicants: ModernaTX, Inc., Fundacion Para La Investigacion Medica AplicadaInventors: Paolo MARTINI, Stephen HOGE, Kerry BENENATO, Vladimir PRESNVAK, Lei JIANG, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Antonio FONTANELLAS ROMA, Pedro BERRAONDO LOPEZ, Matias Antonio AVILA ZARAGOZA, Lin Tung GUEY, Staci SABNIS -
Patent number: 11390854Abstract: The present disclosure relates to human porphobilinogen deaminase derived proteins and polynucleotides and methods of using these proteins and polynucleotides.Type: GrantFiled: May 18, 2017Date of Patent: July 19, 2022Assignee: Fundacion Para la Investigacion Medica AplicadaInventors: Antonio Fontanellas Roma, Irantzu Serrano Mendioroz, Pedro Berraondo Lopez
-
Publication number: 20210139866Abstract: The present disclosure relates to human porphobilinogen deaminase derived proteins and polynucleotides and methods of using these proteins and polynucleotides.Type: ApplicationFiled: May 18, 2017Publication date: May 13, 2021Inventors: Antonio Fontanellas ROMA, Irantzu Serrano MENDIOROZ, Pedro Berraondo LOPEZ
-
POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
Publication number: 20200085916Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).Type: ApplicationFiled: May 18, 2017Publication date: March 19, 2020Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Lei Jiang, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Antonio Fontanellas Roma, Pedro Berraondo Lopez, Matias Antonio Avila Zaragoza, Lin Tung Guey, Staci Sabnis -
Patent number: 9957301Abstract: The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patType: GrantFiled: June 24, 2015Date of Patent: May 1, 2018Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Claude Leclerc, Pedro Berraondo Lopez
-
Patent number: 9636024Abstract: Systems and methods for estimating hemodynamic parameters from physiological curve images. A mobile device captures pictures of a physiological monitor display, which are used to extract the relevant physiological curve and upload it to an analysis server for processing and estimation of hemodynamic parameters. In some examples, the mobile device runs a dedicated application and is Internet-connected, which in turn connects to an Internet-connected analysis server. In some further examples, the system can be implemented using any computer that is capable of taking an image, extracting a physiological curve, and uploading it to a network service for analysis. In still further examples, analysis can be performed by the mobile device instead of via a remote server.Type: GrantFiled: December 29, 2015Date of Patent: May 2, 2017Inventors: Oscar Alvarez Guerras, Borja Barrachina Larraza, Pedro Berraondo Lopez
-
Publication number: 20160110865Abstract: Systems and methods for estimating hemodynamic parameters from physiological curve images. A mobile device captures pictures of a physiological monitor display, which are used to extract the relevant physiological curve and upload it to an analysis server for processing and estimation of hemodynamic parameters. In some examples, the mobile device runs a dedicated application and is Internet-connected, which in turn connects to an Internet-connected analysis server. In some further examples, the system can be implemented using any computer that is capable of taking an image, extracting a physiological curve, and uploading it to a network service for analysis. In still further examples, analysis can be performed by the mobile device instead of via a remote server.Type: ApplicationFiled: December 29, 2015Publication date: April 21, 2016Inventors: Oscar Alvarez Guerras, Borja Barrachina Larraza, Pedro Berraondo Lopez
-
Publication number: 20160074475Abstract: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the Apo A molecule.Type: ApplicationFiled: November 20, 2015Publication date: March 17, 2016Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Jesús María PRIETO VALTUEÑA, Pedro BERRAONDO LÓPEZ, Jessica FIORAVANTI
-
Publication number: 20150291665Abstract: The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different pemissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patiType: ApplicationFiled: June 24, 2015Publication date: October 15, 2015Inventors: Claude LECLERC, Pedro Berraondo LOPEZ
-
Patent number: 9095537Abstract: The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a paType: GrantFiled: July 16, 2007Date of Patent: August 4, 2015Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Claude Leclerc, Pedro Berraondo Lopez
-
Patent number: 8771664Abstract: The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA, interleukin 15 and the Sushi domain of the IL15 receptor alpha chain, as well as to the use of these compositions for the stimulation of the immune response in a patient and to therapeutic methods for the treatment of infectious and neoplastic diseases.Type: GrantFiled: December 10, 2010Date of Patent: July 8, 2014Assignees: Fundacion para la Investigacion Medica Aplicada, Research Center BorstelInventors: Pedro Berraondo Lopez, Jessica Fioravanti, Jose Medina Echeverz, Ignacio Javier Melero Bermejo, Maria del Carmen Ochoa Nieto, Francisco de Asis Palazon Garcia, Silvia Bulfone-Paus, Erwin Hans Duitmann
-
Publication number: 20120244118Abstract: The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA, interleukin 15 and the Sushi domain of the IL15 receptor alpha chain, as well as to the use of these compositions for the stimulation of the immune response in a patient and to therapeutic methods for the treatment of infectious and neoplastic diseases.Type: ApplicationFiled: December 12, 2010Publication date: September 27, 2012Applicants: FUNDACION PARA LA INVESTIGACION MEDICA APLICADA, RESEARCH CENTER BORSTELInventors: Pedro Berraondo Lopez, Jessica Fioravanti, Jose Medina Echeverz, Ignacio Javier Melero Bermejo, Maria del Carmen Ochoa Nieto, Francisco de Asis Palazon Garcia, Silvia Bulfone-Paus, Erwin Hans Duitmann
-
Publication number: 20120237535Abstract: The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells.Type: ApplicationFiled: September 10, 2010Publication date: September 20, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Pedro Berraondo-Lopez, Juan Jose Lasarte Sagastibelza, Christina Mansilla Puerta, Jesus Maria Prieto Valtuena, Pablo Sarobe Ugarriza
-
Publication number: 20110293557Abstract: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule.Type: ApplicationFiled: June 12, 2009Publication date: December 1, 2011Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Jesús Maria Prieto Valtueña, Pedro Berraondo López, Jessica Fioravanti
-
Publication number: 20100150999Abstract: The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patiType: ApplicationFiled: July 16, 2007Publication date: June 17, 2010Inventors: Claude Leclerc, Pedro Berraondo Lopez
-
Publication number: 20080152665Abstract: The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a paType: ApplicationFiled: July 16, 2007Publication date: June 26, 2008Inventors: Claude Leclerc, Pedro Berraondo Lopez